生成生物医药 GENB

Paul Parker, M.B.A., has served as a member of our board of directors since June 2025. Mr. Parker has also served as managing partner of capital solutions and value realization at Flagship Pioneering since September 2024. Previously, Mr. Parker held multiple leadership roles at Thermo Fisher Scientific Inc. (NYSE: TMO) from April 2020 to August 2024, most recently as senior vice president, head of strategy and corporate development, as well as at Goldman Sachs from August 2014 to February 2020, where he served as co-chairman of the Global Mergers and Acquisitions Group. Mr. Parker previously served as a member of the Board of The Clorox Company (NYSE: CLX) from November 2020 to November 2024. He earned an M.B.A. with distinction from Harvard Business School and a B.A. in international studies from the University of North Carolina at Chapel Hill.

Dr. Frances H. Arnold, Ph.D., has served as a member of our board of directors since July 2019. Dr. Arnold manages a research group, is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry, and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center, all at the California Institute of Technology. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Her laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals, and medicine. Dr. Arnold is the recipient of numerous honors, including the Nobel Prize in Chemistry, the Millennium Technology Prize, induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Dr. Arnold has also served as a director of Alphabet Inc. (NASDAQ: GOOG) since October 2019 and Illumina, Inc. (NASDAQ: ILMN) since January 2016. Dr. Arnold holds a B.S. in mechanical and aerospace engineering from Princeton University and a Ph.D. in chemical engineering from the University of California, Berkeley.

Stephane Bancel, M.B.A., has served as a member of our board of directors since September 2019. Mr. Bancel has served as Moderna's chief executive officer since October 2011 and a venture partner at Flagship Pioneering since May 2013. Before joining Moderna, Mr. Bancel served for five years as CEO of the French diagnostics company bioMerieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMerieux. Mr. Bancel has been a member of Moderna's board of directors since March 2011 and of Qiagen N.V.'s (NYSE: QGEN) board of directors from June 2013 to June 2021. Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and was elected to the U.S. National Academy of Engineering in 2024. Mr. Bancel holds an M.B.A. from Harvard Business School, a Master of Science degree in chemical engineering from the University of Minnesota and Master of Engineering degree from Ecole Centrale Paris.

Beth Grous has served as our Chief People Officer since April 2023. She has also served as a part-time venture advisor at SemperVirens Venture Capital since January 2019 and has served on the board of directors of the Tripadvisor Foundation since September 2015. Previously, Ms. Grous served as the senior vice president and chief people officer at Tripadvisor, Inc. (NASDAQ: TRIP) from September 2015 to March 2023. Prior to that role, she served as senior vice president of global human resources at Nuance Communications, Inc., as well as vice president and head of human resources at Sanofi S.A.'s Boston hub. She holds a B.A. in English from Cornell University.

Laurie Lee, M.D., has served as our Chief Medical Officer since September 2025. Previously, Dr. Lee served as vice president of research and development, transplant and immunology, at CSL Behring from April 2020 to September 2025. Prior to joining CSL Behring, Dr. Lee served in multiple roles at GlaxoSmithKline plc (GSK), including as vice president of research and development and medicine development leader. Dr. Lee is a board-certified physician in pediatrics, allergy and immunology. She earned her M.D. from the Ohio State University College of Medicine, and her B.S. in biology from the University of Notre Dame. Dr. Lee completed a residency at Columbus Children's Hospital and fellowship in allergy and immunology at Duke University Medical Center, where she subsequently joined the pediatrics faculty.

Sean Martin, J.D., has served as our Chief Legal Officer and General Counsel since April 2022. Previously, Mr. Martin served as general counsel and senior vice president at Baxter International Inc. (NYSE: BAX) from February 2017 to April 2022. Prior to that role, he was general counsel, senior vice president and secretary at Apollo Education Group, Inc. He also served as vice president for commercial law and corporate law at Amgen Inc. and vice president and deputy general counsel for litigation at Fresenius Medical Care North America. Earlier in his career, Mr. Martin was a law firm partner at Foley & Lardner LLP and served as an Assistant U.S. Attorney in Chicago for eight years, prosecuting federal criminal cases. Mr. Martin holds a J.D. from Harvard Law School and a B.A. in history from the University of Michigan.

Aarif Khakoo, M.D., M.B.A., has served as our Chief Scientific Officer since January 2026. He is also an adjunct clinical associate professor at the Stanford University School of Medicine, a role he has held since April 2011. Previously, Dr. Khakoo was chief scientific officer and head of research and development at Scribe Therapeutics, Inc. from December 2023 to January 2026. Prior to that role, he was chief medical officer and head of drug development at Calico Life Sciences LLC from February 2019 to July 2023. Earlier in his career, Dr. Khakoo served in senior research and development roles at Amgen Inc. Dr. Khakoo earned his M.D. from the Columbia University Vagelos College of Physicians and Surgeons, and his M.B.A. from Columbia Business School. He completed his residency in internal medicine at Johns Hopkins Bayview Medical Center, and a fellowship in cardiovascular medicine at the Johns Hopkins University School of Medicine.

Michael Nally, M.B.A., has served as our Chief Executive Officer and as a member of our board of directors since March 2021, and served as our President from March 2021 to February 2026. Mr. Nally has also served as a CEO-Partner at Flagship Pioneering since March 2021. Previously, Mr. Nally served in multiple roles at Merck & Co., Inc. (NYSE: MRK) from August 2003 to March 2021, including most recently as executive vice president and chief marketing officer from January 2019 until March 2021. Additionally, Mr. Nally has served as a member of the board of directors for PPG Industries, Inc. (NYSE: PPG) (PPG Industries) since February 2021. Mr. Nally holds an M.B.A. from Harvard Business School, a degree in accounting and finance from the London School of Economics and a B.A. in economics from Middlebury College.

Dr. Nancy A. Simonian, M.D., has served as a member of our board of directors since June 2024. She served as chief executive officer of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) (Syros) from June 2012 to December 2023 and served as a member of the board of directors until February 2025. From 2001 to October 2011, Dr. Simonian was employed by Takeda and at Millennium, prior to its acquisition by Takeda, most recently as chief medical officer and senior vice president of clinical, medical and regulatory affairs. She currently is a member of the board of directors of Bayer AG (BAYRY), Alltrna, Inc., a private biotechnology company, and of the Damon Runyon Cancer Research Foundation. She previously served as a member of the board of directors of Seagen Inc. and Evelo Biosciences, Inc., each a publicly traded biotechnology company. Prior to joining the biotechnology industry, Dr. Simonian was on the faculty of Massachusetts General Hospital and Harvard Medical School as an assistant professor of neurology. She received a B.A. in biology from Princeton University and an M.D. from the University of Pennsylvania School of Medicine.

Dr. Jason Silvers, M.D., J.D., has served as our Chief Financial Officer since July 2022 and as our President since February 2026. Previously, Dr. Silvers served in multiple roles at Goldman Sachs & Co. (Goldman Sachs) from August 2002 to June 2022, where he became a managing director in 2010 and partner in 2014. Most recently, he co-managed healthcare investment banking for Goldman Sachs in Europe, the Middle East and Africa. Dr. Silvers holds a J.D. from Yale Law School, an M.D. from the Johns Hopkins University School of Medicine and a B.S. in chemistry from Brown University. He also completed one year of a neurosurgical residency at Jackson Memorial Hospital and was awarded the Surgical Intern of the Year distinction.

Dr. Rupert Vessey, B.M. B.Ch., D.Phil., FRCP, has served as a member of our board of directors since June 2024. Dr. Vessey joined Flagship Pioneering as Executive Partner and Chief Scientist in July 2023 after retiring from Bristol-Myers Squibb Company (NYSE: BMY) (Bristol-Meyers Squibb), where he had served as the President of Research and Early Development since 2019. Prior to joining Bristol-Myers Squibb, he was President of Global Research and Early Development at Celgene Corporation from 2015 to 2019. Before joining Celgene Corporation, Dr. Vessey held various research and development senior management positions during his 10-year tenure at Merck. Dr. Vessey has also served as a member of the board of directors of Bio-Techne Corp (NASDAQ: TECH) since July 2019. He graduated from the University of Oxford with degrees in physiological sciences (B.A., M.A.), clinical medicine (B.M., B.Ch.) and a Doctor of Philosophy (DPhil) in molecular immunology.